NR and NMN: What the NAD+ Trials Actually Measured

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors of NAD+, sold widely as longevity supplements. They are not peptides. They belong in this discussion because they are among the most purchased compounds in longevity practice and because they illustrate a distinction that runs through this entire field: moving a biomarker is not the same as producing a benefit.

This guide situates NR / NMN within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

Why NAD+ matters

NAD+ is a coenzyme required for hundreds of reactions, central to energy metabolism as the electron carrier in glycolysis and oxidative phosphorylation. Without adequate NAD+, cells cannot produce ATP efficiently.

It is also consumed as a substrate by several enzyme families, which is the part relevant to aging. Sirtuins, a family of deacetylases implicated in metabolic regulation and stress resistance, require NAD+ and consume it. PARPs, activated by DNA damage, consume NAD+ heavily during repair. CD38, whose expression rises with age, degrades it.

NAD+ levels decline with age in multiple tissues — a well-replicated observation. The hypothesis follows naturally: if NAD+ falls with age and NAD+-dependent processes matter, restoring it might restore function.

In animal work, raising NAD+ has produced improvements in mitochondrial function, insulin sensitivity and various measures in aged rodents. The biology is real and the rationale is coherent.

What the human trials actually measured

Human trials of NR and NMN have consistently demonstrated one thing clearly: they raise blood NAD+ levels, in a dose-dependent and reproducible way. That much is established and not seriously disputed.

The question is what follows. Trials examining clinical and functional endpoints — muscle function, insulin sensitivity, aerobic capacity, cognitive measures, inflammatory markers — have produced mixed and largely modest results. Some report improvements in specific measures in specific populations; others find no significant difference from placebo.

Several honest uncertainties persist. Blood NAD+ is measurable, but whether it reflects levels in the tissues that matter — muscle, brain, liver — is less clear. Whether restoring NAD+ in someone whose decline is age-related but who is otherwise healthy produces meaningful benefit is unresolved. And most trials are short relative to a process unfolding over decades.

The accurate summary is that these compounds reliably hit their surrogate endpoint and have not yet demonstrated the clinical outcomes the marketing implies. That is a substantially better position than most longevity supplements occupy, and it is not the same as proven benefit.

NR versus NMN

Both feed the NAD+ salvage pathway at slightly different points. NMN sits one step closer to NAD+; NR is converted to NMN before proceeding. Debate continues over whether NMN is absorbed intact or dephosphorylated to NR at the intestinal surface first, which would make the practical difference smaller than marketing suggests.

No convincing human evidence establishes clinically meaningful superiority of one over the other. Choosing between them on the current data is largely a matter of preference and cost.

Both are generally well tolerated in trials, with adverse effects comparable to placebo at studied doses.

Regulatory status — and the NMN complication

NR is marketed as a dietary supplement and has been the subject of new dietary ingredient notifications.

NMN's position is more complicated. The FDA has taken the position that NMN is excluded from the dietary supplement definition because it was authorized for investigation as a new drug before being marketed as a supplement — the so-called drug preclusion provision. This has been contested by industry and has created genuine uncertainty about the lawful status of NMN supplements in the United States.

Patients are generally unaware of this, and it is worth knowing that a product's continued availability online does not settle its regulatory status.

Neither compound is an approved drug for any indication. For patients interested in NAD+ biology, it is worth noting that exercise influences NAD+ metabolism and mitochondrial function through mechanisms with far stronger outcome evidence than any precursor supplement.